Gilead Signs $1.5B Deal With China’s Genhouse Bio for Cancer Drug GH31

China, February 17, 2026: Gilead Sciences has entered a major licensing agreement with Chinese biotech company Genhouse Bio to secure exclusive worldwide rights to GH31, an experimental therapy targeting multiple tumor types. The deal underscores Gilead’s expanding focus on oncology and international collaboration in cancer research.

Under the agreement, Gilead will pay $80 million upfront to Genhouse Bio. Additionally, the deal includes potential milestone payments of up to $1.45 billion, contingent on development progress, regulatory approvals, and commercial success. Future royalties on net sales could further enhance the total value of the partnership.

About GH31

GH31 is a MAT2A inhibitor, designed to target tumors with MTAP gene deletions using a precision oncology approach called synthetic lethality. The drug is being evaluated for cancers including lung, pancreatic, bladder, and certain brain tumors. GH31 has received regulatory clearance to begin human clinical trials in both China and the United States, positioning it for global development under Gilead’s guidance.

Strategic Significance

This collaboration strengthens Gilead’s presence in the rapidly growing cancer therapy market, complementing its established antiviral and inflammatory disease portfolio. Genhouse Bio noted that partnering with Gilead accelerates GH31’s path toward global clinical and commercial success by leveraging Gilead’s regulatory and operational expertise.

The deal reflects a broader trend of cross-border partnerships in oncology, combining innovative biotech research from Asia with global pharmaceutical capabilities to bring new therapies to patients worldwide.